Effect and Safety MABs Administration m.3243A>G Mutation Carriers

Exclusion Criteria

• •A potential subject who meets any of the following criteria will be excluded from participation in this study:
• •Use of dabigatran, apixaban, edoxaban or rivaroxaban (DOACs) as anti-coagulants
• •Have a weekly alcohol intake of ≥ 35 units (men) or ≥ 24 units (women)
• •Current history of drug abuse
• •Deficient immune system or autoimmune disease
• •Significant concurrent illness
• •Ongoing participation in other clinical trials with intervention
• •Pregnant or lactating women
• •Psychiatric or other disorders likely to impact on informed consent
• •Patients unable and/or unwilling to comply with treatment and study instructions
• •A history of strokes with signs of extra-pyramidal or pyramidal syndrome
• •Allergy for contrast fluid
• •Peripheral signs of ischemia or vasculopathy
• •Claustrophobia
• •Metal implants
• •Any other factor that in the opinion of the investigator excludes the patient from the study